Virpax Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Virpax Pharmaceuticals prognostiziert ein Gewinnwachstum at 1.9% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 48.7% pro Jahr.

Wichtige Informationen

1.9%

Wachstumsrate der Gewinne

48.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:VRPX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-9	N/A	N/A	1
12/31/2025	N/A	-8	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	1
9/30/2024	N/A	-13	-17	-17	N/A
6/30/2024	N/A	-17	-15	-15	N/A
3/31/2024	N/A	-17	-16	-16	N/A
12/31/2023	N/A	-15	-10	-10	N/A
9/30/2023	N/A	-14	-8	-8	N/A
6/30/2023	N/A	-15	-11	-11	N/A
3/31/2023	N/A	-18	-14	-14	N/A
12/31/2022	N/A	-22	-18	-18	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-18	-20	-20	N/A
3/31/2022	N/A	-15	-18	-18	N/A
12/31/2021	N/A	-12	-15	-15	N/A
9/30/2021	N/A	-9	-10	-10	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-6	-4	-4	N/A
12/31/2020	N/A	-4	-1	-1	N/A
9/30/2020	N/A	-4	-2	-2	N/A
6/30/2020	N/A	-4	-1	-1	N/A
3/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	-3	-1	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VRPX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VRPX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VRPX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von VRPX schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: VRPX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VRPX in 3 Jahren voraussichtlich hoch sein wird

Virpax Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Recent updates

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million.

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

High number of new and inexperienced directors

Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price

New major risk - Revenue and earnings growth

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Shareholder dilution

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million.

Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1)

New major risk - Financial position

Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2)

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing

Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review

Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Novvae Pharmaceuticals Announces Executive Appointments

Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals

Virpax Pharmaceuticals, Inc. Announces Update on Litigation

Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method

New major risk - Market cap size

Virpax Pharmaceuticals, Inc. Announces CFO Changes

New minor risk - Share price stability

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023

Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director

Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology

Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar

Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022

Chairman & CEO recently bought US$102k worth of stock

Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324

Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm

Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee

Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Chairman & CEO recently bought US$100k worth of stock

Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd.

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million.

Virpax: Targeting Pain At Its Source

Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta

Virpax Pharmaceuticals shares surge on Envelta IND update

Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm)

Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken